Generic RAVICTI® Options – Live Updates
Update: Generic Glycerol Phenylbutyrate Expands Availability
July 1, 2026: NUCDF is monitoring the expanding availability of FDA-approved generic glycerol phenylbutyrate oral liquid (1.1 g/mL), the generic equivalent of Ravicti®.
According to the FDA Orange Book, six generic manufacturers have received FDA approval:
- Par Health / PH Health
- Aurobindo Pharma
- MSN
- Teva Pharmaceuticals
- Navinta LLC
- Lupin
FDA approval does not necessarily mean a product is immediately available through specialty pharmacies.
NUCDF will continue to monitor FDA approvals, product availability, and community experiences and will provide updates as additional information becomes available.
Help Us Learn More
If you or your family member has switched to a generic glycerol phenylbutyrate product, we encourage you to complete the NUCDF Generic Ravicti Survey below. Your experience will help us better understand how these products are being used in the UCD community and identify any trends that may be important.
Lupin Launches Authorized Generic Version of Ravicti® in the United States
Mumbai, Naples, October 24, 2025: Global pharma major Lupin Limited (Lupin) today announced the launch of an authorized generic version of Ravicti® (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States. Read the full announcement. Based on current information, Lupin is now available. The product is manufactured by Amgen, but distributed by Lupin.
FDA Approval & Endo / Par Health Announcement
October 20, 2025, Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced the launch of a generic version of RAVICTI® (1.1 gm/mL oral liquid). Availability and pricing details not yet provided. Read the full announcement. The community reports that switching from Ravicti® to the generic version offered by Endo has resulted in a cost reduction of approximately 10–15%.
Co-Pay Assistance
Philanthropic Initiative
In addition, as previously announced at the 2025 NUCDF Family Conference, a separate, fully funded philanthropic initiative to develop an affordable and accessible generic option is also underway.
Updates will be posted to this page as more information becomes available.
NUCDF Support & Updates
In alignment with our mission, NUCDF remains dedicated to supporting all initiatives that enhance access. Our goal is to ensure that patients will have consistent and affordable access to this essential medication. We will continue to seek and share the latest information on this topic as it becomes available.
